RBC Capital analyst Kennen MacKay lowered his price target on Amgen to $182 and kept his Sector Perform rating after its Q3 results. The analyst says the quarter was “in line” with “safe” expectations, even as the company’s core business competition is “slow” to impact sales. MacKay further cites an “astonishing” launch of Aimovig with 100K new patients, but also notes the sales decline against sequential volume growth for Amgen’s Repatha.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.